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Abstract
Among the most crucial rheological characteristics of blood cells within the 
vasculature is their ability to undergo the shape change (i.e., deform). The signifi-
cance of cellular deformability is readily apparent based solely on the disparate 
mean size of human erythrocytes (~8 μm) and leukocytes (10–25 μm) compared to 
the minimum luminal size of capillaries (4–5 μm) and splenic interendothelial clefts 
(0.5–1.0 μm) they must transit. Changes in the deformability of either cell will 
result in their premature mechanical clearance as well as an enhanced possibility of 
intravascular lysis. In this chapter, we will demonstrate how microfluidic devices 
can be used to examine the vascular deformability of erythrocytes and agranular 
leukocytes. Moreover, we will compare microfluidic assays with previous studies 
utilizing micropipettes, ektacytometry and micropore cell transit times. As will be 
discussed, microfluidics-based devices offer a low-cost, high throughput alternative 
to these previous, and now rather ancient, technologies.
Keywords: deformability, hemorheology, red blood cells, white blood cells, 
micropipette assay, ektacytometry, cell transit analysis, microfluidic analysis, 
transfusion medicine
1. Introduction
The circulating cellular elements of blood consist of erythrocytes (red blood 
cells; RBC), leukocytes (white blood cells; WBC) and platelets. The hemorheology 
of these blood cells is unique in that these cells exist in a fluid phase subjected to 
variable, and often extreme, rheological shear stress, viscosity changes and bio-
mechanical obstacles (e.g., capillaries and splenic filtration). Hemodynamically, 
shear stress is induced by the highly variable flow rate of blood within the ~100,000 
kilometers of the human vasculature bed which encompasses both large arteries and 
veins to the capillary beds (Figure 1A) [1]. With an average resting cardiac output 
of approximately 5 L/min, blood flow in the largest artery (i.e., aorta) is approxi-
mately 50 cm/s while flow rates drop to only about 0.03 cm/s in the smallest capil-
laries and return to about 15–40 cm/s in the largest veins (e.g., superior and inferior 
vena cava) [1, 2]. In high flow conditions, RBC reside in the fast flowing central 
axial column of the vessel while WBC (and platelets) are located more peripherally 
Current and Future Aspects of Nanomedicine
2
and prone to mechanical interaction with the endothelial cells lining the blood 
vessels. WBC also have adhesion molecules on their membrane and, if appropriate 
signals (e.g., inflammation) are present, they actively roll on the endothelial cells 
prior to attachment and extravasation (Figure 1A,B). Moreover, the viscosity of 
blood is also variable and is a function of, primarily, red blood cell (RBC) number 
and flow rate. At high RBC counts and high flow rates, blood is highly viscous 
while at low RBC counts and low flow rates (capillaries), blood viscosity is greatly 
reduced. Moreover, as shown in Figure 1C, the rheological stress is further exac-
erbated by the biomechanical stresses induced by the extreme disparity in the size 
of RBC (~8 μm) and WBC (10–25 μm) to the minimum diameter of the vascular 
Figure 1. 
The physiology and morphology of the vascular bed and blood cells imparts unique rheological 
stress on circulating blood cells. Panel A: the vascular bed is composed of blood vessels of various sizes 
which create significant disparity in blood (fluid and cellular) velocity consequent to vessel diameter. The 
fluid flow induces rheological sheer stress while the vessel size can create biomechanical deformation of 
cellular elements. Panel B: shown are the general physical parameters of human RBC and WBC. Note that 
the biconcave RBC is a anuclear while within the WBC, the nucleus:cytoplasm (N:C) ratio of monocytes 
and lymphocytes are quite divergent. RBC cytoplasmic viscosity is primarily defined by hemoglobin while in 
WBC, in addition to the nucleus, the presence of granules and vacuoles also impact intracellular viscosity and 
the aggregate cellular deformability. Panel C: blood cell deformability is crucial during vascular flow due to 
the size disparity between red blood cells and various leukocytes (e.g., monocytes and lymphocytes) and the 
capillary (4–58 μm) and splenic interendothelial clefts (0.5 μm). Panels B,C are drawn approximately to scale.
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capillary beds (4–5 μm) and splenic interendothelial clefts (0.5–1.0 μm) [3, 4]. 
Hence, consequent to both the shear forces, viscosity and biomechanical stresses 
placed on blood cells, a key biologic/physiologic requirement of both RBC and WBC 
within the vascular space is rheological deformability. Biomechanically, the intra-
cellular viscosity and membrane rigidity of the RBC and WBC are the key factors in 
imparting their vascular rheological deformability.
For the anuclear RBC, intracellular viscosity is primarily determined by hemo-
globin content (both absolute content and hemoglobin structure (Figure 1B)). 
RBC membrane deformability/flexibility is primarily imparted by the cytoskeletal 
structure of the cells and, to a lesser extent, the composition of the bilayer itself 
(lipid species, protein content, integral versus peripheral membrane proteins, and 
carbohydrates). For normal RBC the intra- and inter-individual variability of both 
intracellular viscosity is relatively invariant; however, genetic mutations affect-
ing hemoglobin structure (e.g., HbS, α and β thalassemia, HbE mutations) will 
dramatically affect both hemoglobin content and the viscosity of the hemoglobin 
itself. Similarly, the cytoskeletal structure of normal red blood cells is both well 
characterized and consistent within humans. But, as with hemoglobin variants, 
mutations in any component of the cytoskeleton can dramatically affect the discoid 
shape of the RBC and result in size changes and/or altered rigidity or stability of 
the cytoskeleton and cell itself. Indeed, numerous studies have documented that 
changes in either the hemoglobin content or structure (the major determinant of 
viscosity) or mutations to cytoskeletal components (the major determinant of 
membrane rigidity) can exert significant effects on RBC deformability, biologic 
function and in vivo circulation. In evidence of this, both biological conditions and 
pharmacologic agents that affect hemoglobin content and/or viscosity or the RBC 
cytoskeleton alter cellular deformability and have profound in vivo and in vitro 
effects on RBC function and survival [5–16]. Indeed, RBC deformability can be a 
diagnostic indicator of RBC abnormalities and the quality of stored RBC prior to 
transfusion [17–28].
Intracellular viscosity and membrane structure are similarly key to the rheo-
logical deformability of WBC. However, in contrast to RBC, WBC intracellular 
viscosity is more complex and affected by multiple components including the: 
nuclear to cytoplasm (N:C) ratio; intracellular granule composition; presence of 
cytoplasmic vacuoles; as well as the activation state of the immune cell (Figure 1B) 
[28–30]. Similarly, membrane rigidity is also more complex due to: abundance of 
membrane proteins and protein rafts; changes in protein structure and polymeriza-
tion consequent to immune activation; and the variability of the membrane and 
cytoskeletal protein composition of immune cell populations (e.g., monocytes, 
lymphocytes, granulocytes) and subsets (e.g., T cells versus B cells; CD4+ versus 
CD8+ T cells; NK cells) [30–35]. Perhaps surprisingly, despite the biologic impor-
tance of its rheological deformability within the vasculature, WBC deformability is 
both poorly defined and much less understood. Indeed, previous studies on WBC 
have most commonly defined “deformability” as cellular shape change or spreading 
under extrinsic suction (e.g., micropipette aspiration), compression pressure (e.g., 
centrifugation and cell poker/probe), or upon activation induced motility [30–32, 
34–36]. However, vascular deformability is vastly different from cellular shape 
change or spreading which are most commonly induced by immune cell activation 
and, importantly, the actual loss of vascular rheologically-mediated (i.e., fluid 
motion and spatial confinement) deformability. The paucity of data relating to vas-
cular deformability of WBC has, in large part, been due to the absence of suitable 
tools for measuring deformability across the broad range of cell types encompassed 
within leukocyte population. However, the complexity of the leukocyte population 
and resultant changes in rheological deformability upon activation (e.g., granule 
Current and Future Aspects of Nanomedicine
4
release) potentially arising in peripheral blood WBC may be of clinical importance 
as a biomarker of acute or chronic immune activation.
2. Measuring the vascular (rheological) deformability of blood cells
Because of the crucial role that cellular deformability plays in vascular circula-
tion of RBC, methods to quantitate this biomechanical-aspect of normal and 
abnormal RBC has been of interest to hematologists since the 1960s [3, 5–7, 9, 10, 
37–40]. Historically, multiple technological tools have been employed to study RBC 
(but rarely WBC) deformability including: micropipette aspiration; ektacytometry; 
cell transit times; and, most recently, microfluidic analysis.
2.1 Micropipette aspiration
Perhaps the earliest experimental approach to measure RBC deformability 
was the micropipette aspiration (Figure 2). Initial studies examined the abil-
ity of normal and stored RBC to traverse the length of a micropipette of known 
diameter [38]. This early “microfluidic” single cell analytical approach, while very 
low throughput and time consuming, did demonstrate that damaged or stored 
RBC were less deformable than fresh normal RBC. Subsequent variations of these 
micropipette studies further examined the localized elasticity of the membrane 
in both intact cells and RBC ghosts using ever smaller micropipettes to deform a 
small segment of the membrane to characterize static deformability via membrane 
extensional rigidity and bending rigidity. To further characterize dynamic deform-
ability of the cells, the time constants for rapid elastic recovery from extensional 
and bending deformations were also quantitated [41–47]. However, micropipette, 
single-cell aspiration, measurements did not adequately reflect the biomechanical 
heterogeneity of even a relatively homogenous cell population (e.g., normal RBC), 
much less, the highly divergent population of cells encompassed within the WBC 
population. Hence newer methods were devised in an attempt to study large num-
ber of RBC under flow-like conditions. In contrast to RBC, micropipette studies are 
still commonly used to examine leukocytes; though these approaches tend not to be 
focused on rheological deformability [22, 35, 48–53].
2.2 Ektacytometry
Perhaps the most glaring flaw of the various micropipette aspiration approaches 
were their limitation to single cell analyses. To overcome this limitation, ektacytometry 
Figure 2. 
Overview of micropipette aspiration analysis of blood cells. Micropipette-based analyses were first used to 
explore the crucial role of cellular deformability in the circulation of red blood cells. As noted, these single cell 
analyses were low throughput and time consuming. Multiple variation of this technique have been developed 
ranging from whole cell aspiration to localized membrane deformation. Studies could be done on intact cells or 
membrane ghosts.
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was developed. Ektacytometry measures deformability by suspending RBC in a 
viscous solution and applying rotational shear stress such that the normal discoid cells 
form ellipsoids which is measured by laser diffraction (Figure 3) [13, 14, 54–57]. The 
extent of ellipsoid formation is dependent on the deformability of the sample popula-
tion. Abnormal RBC can be detected by shifts relative to the scatter intensity pattern 
of normal cells. Abnormal (i.e., non-deformable) cells can result in any combinations 
of left or right shifts in response to hypo- or hypertonicity, and/or a decrease in the 
maximum deformation observed under isotonic conditions. Relative to micropipette 
studies, ektacytometry provided a relative rapid assay to examine RBC. Numerous 
ektacytometry studies have elucidated the profound influence that mean corpuscular 
hemoglobin concentration (hence intracellular viscosity), abnormal hemoglobins, 
cytoskeletal aberrations, drugs and oxidant challenge exert on the cellular deform-
ability [13, 14, 18, 54–64]. Importantly, ektacytometry only measures the “average 
deformability” of a cell population and cannot accurately and efficiently quantify the 
abundance of rigid cells in a bimodal population where both normal and abnormal 
cells are present [57, 65]. In the context of blood banking, ektacytometry has been used 
for assessing RBC following blood bank storage [66–68]. Of note, ektacytometry has 
been used exclusively in the context of erythrocytes; with no known studies examin-
ing the shear-induced deformability of lymphocytes, neutrophils, monocytes or other 
leukocytes. Thus, despite some promising data regarding its clinical use in transfusion 
medicine, ektacytometry has not become commonly used in transfusion medicine due 
to both the cost of instrumentation and the relatively low throughput of the existing 
testing protocols. Moreover, ektacytometry does have some significant drawbacks as 
it cannot, without experimental manipulations (e.g., density separation), provide any 
information on subsets of cells within the larger population—the results obtained are 
simply the “average” of the population. This limitation is, perhaps, the critical failure 
of ektacytometry because, in many pathologic states, abnormal RBC represent a minor 
(<10%) fraction of the overall RBC mass hence subtle changes will not be clearly 
obvious. Moreover, it is difficult to recover RBC subsequent to ektacytometric analysis 
for further biologic testing due to the viscous media utilized and, using traditional 
ektacytometry, the fact that the RBC are irreversibly (in most cases) altered by the 
osmotic gradient employed during the assay.
2.3 Cell transit analysis
In contrast to micropipette analysis and ektacytometry, cell transit analysis 
provides information at both the single cell and populational level (Figure 4). 
Figure 3. 
Overview of ektacytometric analysis of blood cells. To overcome the single cell limitations inherent to 
micropipette aspiration, the ektacytometer can analyze the shear-induced deformability of a much larger 
population of RBC; though at the expense of information of single cell data acquisition. Ektacytometry 
measures deformability by subjecting RBC suspended in a viscous solution to rotational shear stress such that 
the normal cells form ellipsoids. The scatter intensity pattern from laser diffraction produces isointensity 
curves and deformability indices. Additionally, the most common approach of ektacytometry examines RBC 
deformability over a broad osmotic gradient (hypotonic → isotonic → hypertonic). Deformability is measured 
via laser diffraction as the shear stress forces the RBC to assume an elongated shape.
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To accomplish this, cell transit analysis combines features of both the traditional 
micropore filtration assay and the micropipette aspiration methodology, in that 
deformability of each RBC constitutes a single data point and can be used to then 
generate a populational distribution curve. In a cell transit analyzer, a single RBC 
passes through a micropore of fixed diameter and length with the transit time (in 
milliseconds; ms) of the cell calculated using the electrical resistance generated by 
the RBC within the channel as detected via a conductometer. However, the sensitiv-
ity of this method varies with cell size. Smaller cells, even if less deformable, pass 
through the pores with less resistance. In contrast, abnormally large or rigid cells, 
which are clinically important, are also be problematic as they block the micropore 
and are excluded from analysis [17, 69, 70]. Despite these limitations, cell transit 
analysis is very useful in that it provides subset/heterogeneity analysis via binning 
of the cells based on the transit time thus providing a continuous measure of the 
deformability profile of a sample and/or the severity of the deformability defect. 
The comparative utility of ektacytometry and cell transit analysis of RBC can be 
seen in normal and model ß thalassemic RBC in which purified alpha-hemoglobin 
chains are entrapped within normal RBC (Figure 5) [17, 19, 61–63]. While the 
ektacytometry and cell transit analysis have proven very useful as research tools, 
they have not been used to any great extent clinically. This is in large part due to 
the expense and complexity of the devices as well as their slow throughput making 
them impractical for clinical laboratories. Moreover, these in vitro studies often 
lack biological validation to the very low throughput of the assay (e.g., micropipette 
aspiration studies), overly small cell numbers, difficulty/impossibility of cell 
recovery post assessment, or more importantly, an inability to either identify or col-
lect specific sample subsets (e.g., low versus high deformability) following analysis 
(e.g., Ektacytometry and Cell Transit Analysis studies).
2.4 Microfluidics
As noted in the preceding discussion, multiple micro/macro fluidic approaches 
have been used to model hemorheology of circulating blood cells; albeit almost 
exclusively RBC. Despite their valuable contributions to our understanding of blood 
cell deformability, these methods are inherently low throughput and dependent on 
relatively expensive instrumentation. But perhaps one of the biggest issues chal-
lenging these previous methodologies is the inability to recover substantial, or any, 
subpopulations (e.g., highly versus poorly deformable cells) from the analyzed 
sample. This weakness precludes additional in vitro or in vivo studies to tease out 
biological variations leading to the differential deformability profiles. Microfluidics 
approaches (Figure 6) potentially offers a cost-effective, high throughput, 
Figure 4. 
Overview of cell transit analysis of blood cells. In contrast to micropipette analysis and ektacytometry, cell 
transit analysis provides information at both the single cell and populational level. Cellular deformability is 
indirectly measured via transit time (ms) of RBC through pores of defined diameter and length. Transit time is 
measured by the change in electrical resistance as an RBC passes through a micropore. Cell transit analysis is, in 
essence, an early micro (macro) fluidics approach.
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alternative to assessing blood cell deformability relative to these previous, and now 
rather ancient (as reflected by the key research papers relating to these approaches) 
technologies [22–25, 27, 28, 71–78]. Deformability measurement using microfluidics 
uses minute amounts of a whole blood or purified RBC/WBC in suspension flowing 
through a funnel-shaped micro-constriction(s) in a disposable plate. As demon-
strated in our previous publications, and discussed in the following section, micro-
fluidics devices are capable of providing reproducible intra- and inter-individual 
data, detecting oxidatively damaged RBC, identifying changes in RBC deformabil-
ity consequent to storage, and identifying leukocytes [20–28].
3. Utility of microfluidics in transfusion medicine
As evidenced by the number of publications and patents being generated annu-
ally, the promise of microfluidic devices in medicine is seemingly unbounded. One 
area of particular interest to our laboratories has been in the field of transfusion 
medicine [20–28]. Annually over 100,000,000 units of blood are collected world-
wide for transfusion purposes. Despite the volume collected, our tools for assessing 
the quality of the stored blood products remains primarily centered on 1950–80s 
technology. Upon collection of whole blood in Canada the blood is processed to 
produce 3 major components: RBC, platelets and plasma. The RBC component for 
Figure 5. 
Comparative data of normal versus model ß thalassemic RBC as assessed by ektacytometry and cell transit 
analysis. Panel A: as shown, ektacytometry provides the mean diffraction profile of a population of cells over 
a broad osmotic gradient; however, it does not provide any information as to the deformability distribution 
of the cells within the total population. Panel B: cell transit analysis gives information regarding both the 
deformability profile of the entire population and the individual cells within the tested population. Data 
derived from Refs. [17, 63].
Figure 6. 
Overview of microfluidic analysis of blood cells. Recent advances in microscale fabrication technologies have 
allowed for the development of an exceedingly broad array of microfluidic devices that may have utility in 
assessing the deformability of blood cells. These approaches range from single to multi-channel devices with 
channels of single or variable lengths and diameters. In addition, some designs incorporate collection ports 
so that cell exhibiting differential deformability profiles can be collected for further in vitro or in vivo study. 
Device shown is adapted from Guo et al. and Kang et al. [26, 28].
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use in blood transfusion therapy are stored at 4°C for up to 42 days. The maximum 
storage window for RBC is based on studies dating from the 1950s on that defined 
a ≥ 75% recovery rate at 24 hours post-transfusion as the clinical “quality control” 
standard for stored donor RBC [79, 80]. Despite decades of research into RBC 
biology and advances in other aspects of transfusion medicine, the 24 hour survival 
rule remains the current gold standard for determining acceptable donor RBC qual-
ity in transfusion medicine. Currently there are no other established biomarkers 
by which blood services can discriminate “good” versus “bad” units. Note however, 
that ultimately the survival of the donor RBC is consequent to their vascular 
deformability (which is in turn governed by a multitude of biologic/metabolic fac-
tors). Hence, cost effectively assessing the deformability of stored RBC could serve 
as an excellent biomarker for the quality of stored donor RBC. Intriguingly, RBC 
deformability may also be a potent pre-screening tool that could be used to exclude 
potential donors from RBC donations. RBC which demonstrate poor initial deform-
ability upon collection do not store well and may lead to adverse events in patients 
who receive these units. Poor deformability of potential donor RBC may arise from 
a broad range of issues including: undiagnosed RBC abnormalities (e.g., cytoskel-
etal, hemoglobin or metabolic aberrations); vascular inflammation; or dietary or 
drug-mediated alterations of the RBC.
To assess the deformability of blood cells, our laboratories have utilized a variety 
of microfluidic devices ranging from a simple, low throughput, funnel chain 
(prone to clogging) to a much more advanced and robust high throughput ratchet 
device. The ratchet microfluidic approach has proved better at assessing vascular 
deformability as blood cells are pushed laterally and vertically through tapered 
microchannels of decreasing size thus modeling the process of cellular deforma-
tion in microvasculature (Figure 7). Vertical movement is done via an oscillatory 
vertical pressure deferential that allows both a net vertical filtration flow and a 
downward declogging flow to minimize microchannel obstruction by blood cells 
as they reach their deformability limit. Importantly, this design also incorporates 
collection outlets allowing for recovery, and further testing, of cell populations with 
differential deformability profiles. Our research to date has demonstrated that this 
microfluidic microfiltration device is capable of isolating circulating tumor cells 
Figure 7. 
General schematic of a ratchet microfluidic device. Panel A: shown is a photograph of the ratchet microfluidic 
device infused with different color dyes to highlight the design features: cross flow inlet (a), sample inlet (b), 
upward (c) and downward (d) oscillatory flow inlets, sorting region (dashed blue box) and outlets 1–8. In this 
design, outlets 8–1 corresponds to blocking pore sizes of ≥6.5, 5.5, 4.5, 4.0, 3.5, 3.0, 2.5 and 2.0 μm, respectively. 
Panel B: schematic of the sorting region showing the decreasing size of the tapered microchannels as well as 
the deformability of normal and oxidized RBC through these microchannels. Poorly deformable cells (e.g., 
oxidized RBC) are collected in outlets 8 and 7 while highly deformable cells are collected in outlets 3 thru 1. 
The downward oscillatory pressure minimizes channel obstruction by poorly deformable cells which are pushed 
horizontally into the collection outlets by the cross flow pressure. This device is suitable for use for both human 
RBC and WBC.
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from leukocytes, malaria-infected and oxidized RBC from normal cells, granulo-
cytes and lymphocytes from whole blood, and detecting early immune cell activa-
tion consequent to degranulation [26–28, 81].
Key to the use of microfluidic devices in RBC blood banking is documenting 
the ability of the device(s) to discriminate between “normal” and abnormal cel-
lular deformability and document that the loss of deformability is associated with 
diminished in vivo circulation. Loss of cellular deformability can arise from a 
host of causes, most of which, due to the iron and oxygen rich environment of the 
RBC, leads to cellular oxidation [17–19, 23, 57, 61, 63, 82]. As shown in Figure 8, 
human or murine RBC oxidized by exposure to 50 μM phenazine methosulfate 
(PMS) were readily discriminated from normal RBC as measured by the cortical 
tension required to push the RBC through a funnel shaped micropore However, 
as noted by the differences between the human and murine RBC, the microchan-
nel size (2–2.5 μm in this experiment) relative to the mean diameter of the RBC 
itself (~8 versus 6.7 μm for human and mouse RBC, respectively) will also play a 
role. Most importantly however, the loss of murine deformability in the oxidized 
RBC sample, as noted in the microfluidic device, correlated closely with the loss of 
in vivo survival. These findings suggest that microfluidic devices could prove useful 
for both diagnostic purposes (e.g., hemoglobinopathies such as sickle cell disease 
and thalassemia) as well as in evaluating the quality of stored human RBC prior to 
transfusion into a patient.
Indeed, microfluidics analysis of stored human RBC suggests that deformability 
is affected by storage time. As demonstrated by Matthews et al., using a microflu-
idic device, there is a significant loss of RBC deformability as early as 2 weeks into 
storage [25]. This finding confirms single-cell deformability studies that similarly 
Figure 8. 
Analysis of human and murine RBC deformability using a conical microfluidic array. The width of the 
funnel shaped micropore constriction used to measure RBC deformability was approximately 2–2.5 μm in 
size at its minimum. (a) and (b) equals peak count for oxidized and normal RBC respectively. Human blood 
was obtained via a finger prick while mouse blood was obtained by saphenous bleed. Also noted is the 50% 
in vivo survival point for oxidized (~5 days) and normal (~26 days) murine RBC. Data derived from Kwan 
et al. [23].
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indicated that RBC deformability remained fairly constant in the first 2–3 weeks of 
storage and then rapidly decreased [83, 84]. However, in contrast to these single cell 
studies, our high throughput device can rapidly assess the proportion of individual 
RBCs that are too rigid to transit the microconstrictions and may, upon transfusion 
into an individual, be cleared by the spleen. Indeed, by day 42 of storage, 30% of 
all donor RBCs were too rigid to transit the device. Interestingly, a small subset of 
donors had RBC that demonstrated poor storage in that >50% of their RBC were too 
rigid to passage the microconstriction. These research findings suggest that the RBC 
quality of individual donors are, not unexpectedly, variable. The source of inter-
individual variability causing the poor storage could be either inherent to the donor 
RBC itself (e.g., metabolic, structural or hemoglobin abnormalities) or transient 
(e.g., inflammation, food or drug induced).
The prescreening questionnaire completed by both new and repeat blood donors 
is focused, in part, on identifying factors that could adversely affect the quality of 
the blood product(s) produced from a donation. While most biologically-mediated 
RBC defects are likely to have been previously detected during normal medical sur-
veillance of the prospective donor, transient inflammatory-mediated effects, such 
as those arising from viral, bacterial, drug or autoimmune events, are most likely 
to impact blood component quality. To address these potential risks, at the time of 
blood donation, all donors are asked if they feel ill or have had a recent fever. While 
the primary purpose of these self-reporting questions is to avoid transfusion of 
blood-borne infective agents or plasma that may contain potent immunomodula-
tory chemokines and cytokines, systemic inflammatory events may also result in 
bystander injury to the RBC that may compromise RBC storage and safety. The 
described microfluidics ratchet device may also provide a means of assessing both 
the WBC population and activation state of an individual [26, 28]. As shown in 
Figure 9, the ratchet microfluidic device described in Figure 7, is capable of dif-
ferentially sorting monocytes from lymphocytes. The same device can also differ-
entiate between resting (granule containing) from activated (degranulated) CD8+ 
T lymphocytes. Further refinement of the microchannel geometry will be capable 
of improving cell separation making it possible to readily prescreen individuals for 
evidence of immune activation thus improving blood component safety consequent 
to empirical donor evaluation versus self-reporting. Finally, microfluidic devices 
Figure 9. 
Analysis of human monocyte and lymphocyte populations showing differential sorting on the ratchet 
microfluidic device. Note that the prototype device can also detect degranulation of lymphocytes (shown are 
CD8+ T cells) which occurs upon inflammatory activation. The vertical dashed line separates cells based on 
less deformable (collection outlets 8–6) and more deformable (collection outlets 5–3). Data derived from Kang 
et al. [28].
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could also be used during the blood collection process, as well as in the field, to 
screen individuals who have reported recent travel to malarial endemic areas, for 
actual malaria infection [27, 85–88]. Currently, individuals traveling to malarial 
endemic regions are deferred from blood donation; an action that often results in 
their permanent loss from the blood donor pool.
4. Conclusions
Microfluidics devices have the potential to dramatically, and cost-effectively, 
change the practice of transfusion medicine. As illustrated, purpose-specific 
development of ratchet microfluidics devices will make it possible, via a finger 
prick (e.g., as shown in Figure 8), to prescreen donors at the time of pre-donation 
testing (i.e., simultaneously with determining the donor’s hematocrit prior to unit 
donation) to select donors whose RBC show normal deformability profiles prior 
to storage. Donors with RBC deformability profiles outside of the normal range 
would be deferred from RBC donation, though potentially, still donating plasma 
for fractionation into plasma protein components. Moreover, the same microfluidic 
approach could improve the detection of patients with recent/current systemic 
immune activation that could result in the presence of undesirable cytokines/
chemokines within the donated blood or that might have adversely affected normal 
RBC deformability. Hence, the cost-effective microfluidic-based prescreening 
process would potentially diminish the risk to patient safety that accompanies 
ineffectual RBC transfusion and/or the presence of inflammatory mediators in 
blood products. Not inconsequentially, prescreening for good donors would reduce 
the expense to the blood operator associated with the production and distribution 
of a potentially ineffectual, or unsafe, blood unit. Beyond prescreening donors, 
patient safety would also be enhanced by doing point-of-care deformability analysis 
of stored RBC prior to transfusion. Such analysis would enhance patient safety by 
reducing the aggregate transfusion needs of a patient by preventing the transfusion 
of RBC which would have poor in vivo survivability. Such an approach would be of 
particular value in the chronically transfused patient (e.g., sickle cell, thalassemic 
and myelodysplastic) populations.
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